📊 Q3 Earnings are here! Plan ahead with key data on upcoming stock reports - all in 1 placeSee list

Grifols SA Pref (GRFPe)

BATS Europe
Currency in EUR
Disclaimer
8.03
0.00(0.00%)
Closed
GRFPe Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
8.038.09
52 wk Range
4.9410.39
Bid/Ask
8.18 / 8.32
Prev. Close
8.03
Open
8.09
Day's Range
8.03-8.09
52 wk Range
4.94-10.39
Volume
0
Average Volume (3m)
11,268
1-Year Change
0.12%
Fair Value
Unlock
Fair Value Upside
Unlock
GRFPe Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
11.56
Upside
+44.45%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

Grifols SA Pref Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Employees
23000
Market
Spain

Compare GRFPe to Peers and Sector

Metrics to compare
GRFPe
Peers
Sector
Relationship
P/E Ratio
38.2x−0.1x−0.6x
PEG Ratio
0.010.070.00
Price/Book
1.1x1.7x2.6x
Price / LTM Sales
0.9x5.0x3.3x
Upside (Analyst Target)
-93.0%49.0%
Fair Value Upside
Unlock11.2%7.7%Unlock

FAQ

What Is the Grifols Pref (GRFPe) Stock Price Today?

The Grifols Pref stock price today is 8.03.

What Stock Exchange Does Grifols Pref Trade On?

Grifols Pref is listed and trades on the BATS Europe stock exchange.

What Is the Stock Symbol for Grifols Pref?

The stock symbol for Grifols Pref is "GRFPe."

What Is the Grifols Pref Market Cap?

As of today, Grifols Pref market cap is 6.32B.

What is Grifols Pref Earnings Per Share?

The Grifols Pref EPS is 0.229.

What Is the Next Grifols Pref Earnings Date?

Grifols Pref will release its next earnings report on 06 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.